Equity Overview
Price & Market Data
Price: $5.21
Daily Change: -$0.0499 / 0.96%
Daily Range: $5.17 - $5.54
Market Cap: $54,322,220
Daily Volume: 11,413
Performance Metrics
1 Week: -1.62%
1 Month: -4.39%
3 Months: -5.22%
6 Months: 17.97%
1 Year: -40.24%
YTD: 8.78%
Company Details
Employees: 13
Sector: Commercial services
Industry: Miscellaneous commercial services
Country:
Details
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.